STRATHCLYDE PHARMACEUTICALS LIMITED
Get an alert when STRATHCLYDE PHARMACEUTICALS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-07 (in 5mo)
Last made up 2025-09-23
Watchouts
None on the register
Cash
£426K
+120.5% vs 2023
Net assets
£4M
-2.9% vs 2023
Employees
44
+2.3% vs 2023
Profit before tax
-£122K
+63.3% vs 2023
Net assets
7-year trend · vs Consumer Discretionary median
Accounts
7-year trend · latest reflected 2024-12-31
| Metric | Trend | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-09 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | £24,171,559 | £24,330,016 | |
| Operating profit | — | — | — | — | — | -£256,918 | -£74,248 | |
| Profit before tax | — | — | — | — | — | -£331,109 | -£121,620 | |
| Net profit | — | — | — | — | — | -£331,109 | -£121,620 | |
| Cash | — | — | — | — | — | £193,270 | £426,090 | |
| Total assets less current liabilities | — | — | — | — | — | £4,178,616 | £4,056,996 | |
| Net assets | — | — | — | — | — | £4,178,616 | £4,056,996 | |
| Equity | £15,065,276 | £14,099,714 | £13,616,475 | £5,207,983 | £4,509,725 | £4,178,616 | £4,056,996 | |
| Average employees | — | — | — | — | — | 43 | 44 | |
| Wages | — | — | — | — | — | £1,020,072 | £1,085,218 | |
| Directors' remuneration | — | — | — | — | — | £81,878 | £83,137 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+0.7%
£24,171,559 £24,330,016
-
Cash
+120.5%
£193,270 £426,090
-
Net assets
-2.9%
£4,178,616 £4,056,996
-
Employees
+2.3%
43 44
-
Operating profit
+71.1%
-£256,918 -£74,248
-
Profit before tax
+63.3%
-£331,109 -£121,620
-
Wages
+6.4%
£1,020,072 £1,085,218
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-09 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | — | — | — | — | — | -1.1% | -0.3% | |
| Net margin | — | — | — | — | — | -1.4% | -0.5% | |
| Return on capital employed | — | — | — | — | — | -6.1% | -1.8% | |
| Current ratio | — | — | — | — | — | 2.18x | 1.98x | |
| Interest cover | — | — | — | — | — | -3.46x | -1.57x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- STRATHCLYDE PHARMACEUTICALS LIMITED 2013-06-19 → present
- SPL (2004) LIMITED 2004-09-23 → 2013-06-19
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Bannerman Johnstone Maclay
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Significant events
- “The directors are disappointed with the results for the period but would note that the underlying trading loss was less than the previous year. Market conditions remain challenging but the directors are confident that the company will return to profitability and remains well placed to take advantage of future opportunities.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 8 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GORRELL, Shirley Agnes | Director | 2013-06-19 | Nov 1967 | British |
| OGLE, Jason | Director | 2022-06-21 | Mar 1979 | Irish |
| WADDING, Patrick Michael | Director | 2022-03-09 | Jul 1968 | Irish |
| WADDING, Sandra Catherine | Director | 2022-03-09 | Jun 1973 | Irish |
Show 8 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BAXTER, Anthony | Secretary | 2006-02-01 | 2009-07-31 |
| LINTS, Simon Philip | Secretary | 2004-09-23 | 2006-01-31 |
| BAXTER, Anthony | Director | 2006-02-01 | 2009-07-31 |
| BELL, Graeme Davie | Director | 2004-09-23 | 2005-11-30 |
| COCHRANE, John | Director | 2006-02-01 | 2022-03-09 |
| LINTS, Simon Philip | Director | 2004-09-23 | 2006-01-31 |
| MCGROARY, Dianne | Director | 2006-02-01 | 2008-02-29 |
| MUNRO, Donald Hume | Director | 2004-09-23 | 2013-11-28 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| P.C.O. Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-03-09 | Active |
| Munro Healthcare Group Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Ceased 2022-03-09 |
Filing timeline
Last 20 of 94 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-22 | AA | accounts | Accounts with accounts type full | |
| 2024-09-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-18 | AA | accounts | Accounts with accounts type full | |
| 2023-09-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-09-26 | AA | accounts | Accounts with accounts type full | |
| 2023-06-08 | AA01 | accounts | Change account reference date company previous shortened | |
| 2022-12-21 | AA | accounts | Accounts with accounts type full | |
| 2022-12-20 | AA01 | accounts | Change account reference date company previous shortened | |
| 2022-09-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-06-23 | AP01 | officers | Appoint person director company with name date | |
| 2022-03-31 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-03-31 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-03-31 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-03-31 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-03-25 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2022-03-25 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2022-03-24 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2022-03-23 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2022-03-23 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.